FY2025 EPS Estimate for CervoMed Decreased by Analyst

CervoMed Inc. (NASDAQ:CRVO) – Stock analysts at Chardan Capital cut their FY2025 earnings estimates for shares of CervoMed in a research note issued to investors on Monday, March 24th. Chardan Capital analyst D. Gataulin now expects that the company will earn ($2.68) per share for the year, down from their prior forecast of ($1.22). Chardan Capital currently has a “Buy” rating and a $14.00 target price on the stock. The consensus estimate for CervoMed’s current full-year earnings is ($1.88) per share.

CRVO has been the subject of several other research reports. HC Wainwright lowered CervoMed from a “buy” rating to a “neutral” rating in a research note on Tuesday, December 17th. Roth Mkm increased their target price on shares of CervoMed from $15.00 to $20.00 and gave the company a “buy” rating in a report on Tuesday, March 18th. Jones Trading upgraded shares of CervoMed from a “hold” rating to a “buy” rating and set a $15.00 target price on the stock in a research report on Thursday, March 13th. D. Boral Capital restated a “buy” rating and set a $10.00 price target on shares of CervoMed in a research report on Wednesday. Finally, Canaccord Genuity Group lifted their price objective on CervoMed from $12.00 to $21.00 and gave the stock a “buy” rating in a report on Tuesday, March 18th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, five have given a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $27.50.

CervoMed Trading Down 12.9 %

Shares of CervoMed stock opened at $7.71 on Thursday. The firm has a market capitalization of $67.10 million, a PE ratio of -3.80 and a beta of 1.84. CervoMed has a 12 month low of $1.80 and a 12 month high of $25.92. The business’s 50-day moving average price is $3.72 and its 200-day moving average price is $7.68.

CervoMed (NASDAQ:CRVO) last released its earnings results on Monday, March 17th. The company reported ($0.80) EPS for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.13). CervoMed had a negative net margin of 118.68% and a negative return on equity of 44.11%. The firm had revenue of $2.16 million during the quarter, compared to the consensus estimate of $1.51 million.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Geode Capital Management LLC lifted its holdings in CervoMed by 13.9% in the 3rd quarter. Geode Capital Management LLC now owns 114,934 shares of the company’s stock worth $1,678,000 after buying an additional 14,042 shares during the period. State Street Corp raised its stake in CervoMed by 28.1% in the third quarter. State Street Corp now owns 104,456 shares of the company’s stock worth $1,525,000 after buying an additional 22,903 shares in the last quarter. Woodline Partners LP bought a new position in shares of CervoMed in the 4th quarter worth approximately $175,000. Perigon Wealth Management LLC purchased a new position in shares of CervoMed in the 4th quarter valued at approximately $147,000. Finally, Nuveen Asset Management LLC boosted its position in shares of CervoMed by 113.6% during the fourth quarter. Nuveen Asset Management LLC now owns 41,569 shares of the company’s stock valued at $97,000 after purchasing an additional 22,104 shares in the last quarter. Hedge funds and other institutional investors own 25.15% of the company’s stock.

About CervoMed

CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery.